期刊文献+

新型口服抗凝药的临床应用 被引量:3

Clinical application of new oral anti-coagulants
原文传递
导出
摘要 新型口服抗凝药物(NOAC)凭借其无需频繁监测凝血指标、药物食物相互作用较少、出血等并发症发生率较低等优点,在抗凝治疗中的地位不断上升。目前,NOAC已被广泛应用于非瓣膜性心房颤动、静脉血栓栓塞等病变的抗凝治疗之中。然而,针对不同的临床情况,NOAC的应用亦有其特点。文章将从NOAC的特征、临床适应证、药物间的转换及出血并发症的处理等方面阐述NOAC的应用。 The status of new oral anticoagulants (NOAC) in anticoagulation therapy is rising rapidly, because of its virtue of low- frequency coagulation monitoring, fewer drug-food interactions and less incidence of bleeding. Currently, NOAC has been widely applied to anticoagulation treatment for non-valvular atrial fibrillation, venous thromboembollsm and other diseases. However, the usage of NOAC has its own characteristics according to different dinical situations. Here, we will describe the clinical features of NOAC regarding its characteristics, clinical indications, transition between anticoagulants and management of bleeding complications in clinical practice.
作者 左嵩 马长生
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2016年第4期261-264,共4页 Chinese Journal of Practical Internal Medicine
基金 科技部国际合作项目(2013DFB30310)
关键词 口服抗凝药 心房颤动 oral anticoagulants atrial fibrillation
  • 相关文献

参考文献21

  • 1HU D, SUN Y. Epidemiology risk factors for stroke, and management of atrial fibrillation in China[J]. J Am Col Cardiol, 2008, 52(10): 865- 868.
  • 2Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361 ( 12): 1139-1151.
  • 3Patel MR, Mahaffey GargJj et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N EnglJ Med, 2011,365(10): 883- 891.
  • 4Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation[J]. N EngIJ Med, 2011,364(9): 806-817.
  • 5Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2013, 369(22): 2093 -2104.
  • 6非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议[J].中华心血管病杂志,2014,42(5):362-369. 被引量:79
  • 7Dewilde wJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial[J]. Lancet, 2013, 381 (9872): 1107-1115.
  • 8Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[J]. Circulation, 2013, 127 (5): 634-640.
  • 9Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from theARISTOTLE trial[J]. Eur Heart J, 2014, 35(4): 224-232.
  • 10Heidbuchel H, Verhamme P Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary[J]. Eur Heart J, 2013, 34(27): 2094- 2106.

二级参考文献6

共引文献110

同被引文献18

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部